US green light for clinical testing of Proacta's reversible MKI inhibitor
This article was originally published in Scrip
Executive Summary
The US FDA has given Proacta the go-ahead to begin clinical trials of PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.